目的:油菌是一种有价值的食用和药用真菌。在这项研究中,Ergosta-4,6,8(14),22-四烯-3-酮(ETO)是首次从脂肪草获得的,是研究其抗糖尿病和相关机制。
方法:Ergosta-4,6,8(14),22-四烯-3-酮(ETO)由IR和NMR定义。采用ELISA法检测相关生化指标,苏木精-伊红染色(H&E),空腹血糖水平(FBG),口服葡萄糖耐量试验(OGTT),组织匀浆生化测量,免疫组织化学染色和蛋白质印迹。
结果:在这项研究中,ETO治疗组显示空腹血糖(FBG)水平显着降低,高剂量组(HD)比糖尿病对照组(DC)低约10mmol/L,增加体重,HD组比DC组平均重约5g。此外,三酰甘油(TG)的水平,总胆固醇(TC),发现低密度脂蛋白胆固醇(LDL-C)降低,而高密度超氧化物歧化酶(SOD)的水平,脂蛋白胆固醇(HDL-C),过氧化氢酶(CAT),在ETO治疗组中,谷胱甘肽过氧化物酶(GSH-Px)增加。糖尿病对照组(DC)的胰腺和肝脏切片表现出几种组织病理学改变,但ETO治疗组表现出改善。ETO治疗导致胰岛形态和功能的显著恢复。此外,蛋白质印迹分析的结果表明,ETO可用于糖尿病的治疗,因为它修饰了部分IRS1/PI3K/AKT信号通路。
Pholiota adiposa is a valuable edible and medicinal fungus. In this research, Ergosta-4, 6, 8(14), 22-tetraen-3-one (ETO) was obtained from Pholiota adiposa which is the first time to study the anti-diabetic and related mechanism.
Ergosta-4, 6, 8 (14), 22-tetraen-3-one (ETO) was defined by IR and NMR. Relevant biochemical indicators were detected by ELISA assay, hematoxylin-eosin staining (H & E), fasting glucose levels (FBG), oral glucose tolerance test (OGTT), tissue homogenate biochemical measurements, immunohistochemical staining and western blot.
In this research, the ETO treatment groups exhibited a significant reduction in fasting blood glucose (FBG) levels, the High dose group (HD) was about 10 mmol/L lower than the diabetic control group (DC), and increase in body weight, the HD group weighed about 5 g more than the DC group on average. Also, the levels of triacylglycerol (TG), total cholesterol (TC), and low-density lipoprotein-cholesterol (LDL-C) were found to be decreased, while the levels of high-density superoxide dismutase (SOD), lipoproteincholesterol (HDL-C), catalase (CAT), and glutathione peroxidase (GSH-Px) were increased in the ETO treatment groups. The pancreatic and liver sections of diabetic control group (DC) exhibited several
histopathological changes, but the ETO treatment groups exhibited improvements. ETO treatment led to the significant restoration of islet morphology and function. Moreover, the results of the western blot analysis indicate that ETO could be used for the treatment of diabetes, since it modifies part of the IRS1 / PI3K / AKT signaling pathway.